Help them let go of
their transfusions

ZYNTEGLO® is a one-time gene therapy that gives people with beta-thalassemia the potential to become free from regular red blood cell (RBC) transfusions.1

Explore Efficacy

In two open-label, single-arm studies,
89% (n=32/36; 95% CI: 74, 97) of patients achieved
transfusion independence.*†

CI = confidence interval.
*Transfusion independence: a weighted average Hb ≥9 g/dL without any packed red blood cell transfusions for a continuous period of ≥12 months at any time during the study after ZYNTEGLO infusion.1
†The phase 3 studies evaluated the efficacy of ZYNTEGLO in 41 patients. Of those 41 patients, 36 were evaluable for transfusion independence.

Find a Qualified
Treatment Center 
Actor portrayals
Beta-thalassemia transfusion independence Beta-thalassemia transfusion independence
89% (n=32/36; 95% CI: 74, 97) of patients
across ages and genotypes achieved transfusion
independence with a median weighted average total
Hb during TI of 11.5 g/dL (min, max: 9.3, 13.7)1*

*Across clinical trials, patient evaluability for transfusion independence (n=36) was defined as patients who have completed their parent study (ie, 24 months of follow-up), achieved transfusion independence, or will not achieve transfusion independence in their parent study.1

See Full Study Designs

Topics to Explore

MOA Efficacy Safety Treatment Pathway Patient Identification Support

Patient Identification

Patient Identification

ZYNTEGLO is indicated for the treatment of adult and pediatric patients with beta-thalassemia who require regular RBC transfusions.1

Made using the patient’s
own hematopoietic stem cells (HSCs).1

Studied in both adult and
pediatric patients.1

Assessed across all genotypes
(β0/β0 and non-β0/β0).1

*ZYNTEGLO was studied in patients 4 to 34 years of age. The safety and efficacy in children <4 years of age have not been established; no data are available.1

Explore Patient Profiles
Back
to Top

Mechanism of Action

Mechanism of Action

ZYNTEGLO can address the underlying genetic cause of beta-thalassemia by adding functional copies of a modified β-globin gene to the patient’s own hematopoietic stem cells (HSCs).1

More on MOA

Safety Considerations

Safety Considerations

Safety was based on 41 patients treated with ZYNTEGLO in 2 open-label, single-arm clinical studies and 1 long-term follow-up study.1

Read About ZYNTEGLO Safety

Stay Connected

Stay Connected

Keep informed about ZYNTEGLO.